GLAXO RETAINS 3TC HIV DEVELOPMENT OPTION AFTER EUROPEAN PHASE II/III RESULTS
Executive Summary
GLAXO RETAINS 3TC HIV DEVELOPMENT OPTION AFTER EUROPEAN PHASE II/III RESULTS show the nucleoside analog in combination with Burroughs Wellcome's Retrovir (zidovudine) causes significant increases in CD4 cell counts and reductions in viral load in HIV-infected patients, Glaxo said Nov. 20. By retaining its clinical development rights, Glaxo obviates an option calling for Wellcome to assume the clinical development of 3TC (lamivudine) for that indication.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth